A 60+ year old diabetes drug now being studied for anti-aging, healthspan extension, and age-related disease prevention. The TAME trial is the first FDA-approved study designed to test whether a medication can target aging itself. Prescribed off-label for longevity by board-certified physicians.
Metformin activates AMP-activated protein kinase (AMPK), a cellular energy sensor that triggers many of the same downstream pathways activated by caloric restriction — a known lifespan-extending intervention in animal models. It also reduces inflammation, improves insulin sensitivity, and may have anti-cancer effects.
The most striking observational data: follow-up analyses of the UK Prospective Diabetes Study and other large cohorts have found that diabetic patients taking metformin had lower all-cause mortality than non-diabetic controls. A diabetes medication appeared to help sick people live longer than healthy people not taking any medication. This association — while not proof of causation — is what prompted the TAME trial.
Targeting Aging with Metformin (TAME) is the first FDA-approved clinical trial designed to test whether a drug can target aging itself rather than any single disease. It aims to enroll approximately 3,000 participants aged 65–79 to determine whether metformin delays the onset of age-related diseases including heart disease, cancer, dementia, and death. Results will shape how we think about "treating aging" as a medical target.
What we know:
What we don't know yet: definitive randomized evidence that metformin extends lifespan or healthspan in non-diabetic adults. The TAME trial is designed to answer this.
Extended-release (ER) formulation significantly reduces GI side effects compared to immediate-release.
Common: GI upset (diarrhea, nausea, abdominal discomfort) — usually in the first 2–4 weeks and resolves. ER formulation reduces this.
Long-term: B12 deficiency is possible with chronic use; monitor annually.
Rare: Lactic acidosis — extremely rare, seen in patients with severe kidney disease.
Contraindications: severe kidney disease (eGFR <30), active liver disease, metabolic acidosis, heavy alcohol use, before procedures requiring IV contrast.
Metformin for longevity is an off-label use. Candidates are typically healthy adults interested in metabolic optimization, prediabetic patients wanting progression prevention, or longevity enthusiasts building a physician-supervised stack. Your YourMD physician will review baseline labs (kidney function, B12, HbA1c) and discuss what the current evidence does and doesn't tell us.
Medical disclaimer: Off-label use. Educational content, not medical advice. Page medically reviewed by Teja V. Surapaneni, MD, MS (NV, WA, OR, WY). Last reviewed: April 17, 2026